Back to Search
Start Over
Efficacy of Inotuzumab Ozogamicin plus Ponatinib Followed by Allogeneic Stem Cell Transplantation in a Patient with Relapsed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
- Source :
-
Case reports in hematology [Case Rep Hematol] 2021 May 26; Vol. 2021, pp. 1717506. Date of Electronic Publication: 2021 May 26 (Print Publication: 2021). - Publication Year :
- 2021
-
Abstract
- Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) is an aggressive disease with poor outcomes. Despite the incorporation of tyrosine kinase inhibitors (TKIs) in the therapeutic strategies, patients who relapse after chemotherapy plus TKI have poor overall survival (OS) and less chance to proceed to hematopoietic stem cell transplantation (HSCT) which remains the only curative approach. Therefore, new drugs, such as antibody-targeted therapies alone or in combination with TKIs, offer new therapeutic options for those patients. However, the combination of inotuzumab plus ponatinib has limited application. We present a case of a patient affected by Ph + ALL with T315I mutation successfully treated after early relapse with inotuzumab plus ponatinib, followed by allogeneic HSCT and ponatinib maintenance.<br />Competing Interests: The authors declare that they have no conflicts of interest.<br /> (Copyright © 2021 Ilina Micheva et al.)
Details
- Language :
- English
- ISSN :
- 2090-6560
- Volume :
- 2021
- Database :
- MEDLINE
- Journal :
- Case reports in hematology
- Publication Type :
- Report
- Accession number :
- 34136291
- Full Text :
- https://doi.org/10.1155/2021/1717506